Key Points
- Director William Burke sold 18,000 CeriBell shares for about $479,520, reducing his direct stake by 43.88% to 23,022 shares.
- CeriBell’s latest quarter showed a per-share loss of $0.55, missing estimates of $0.51, while revenue of $29.34 million slightly topped expectations.
- Analysts’ consensus rating is Moderate Buy, with a $31.25 average price target; shares traded at $26.14 on Friday.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director William Burke sold 18,000 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $26.64, for a total value of $479,520.00. Following the transaction, the director directly owned 23,022 shares in the company, valued at approximately $613,306.08. This represents a 43.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
CeriBell Stock Performance
CBLL stock traded down $0.21 during trading on Friday, hitting $26.14. The company had a trading volume of 267,634 shares, compared to its average volume of 590,859. The firm has a market cap of $1.02 billion, a PE ratio of -13.47 and a beta of 0.86. CeriBell, Inc. has a 1-year low of $12.40 and a 1-year high of $28.89. The firm has a 50-day moving average price of $25.52 and a 200-day moving average price of $21.04. The company has a quick ratio of 7.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. The company had revenue of $29.34 million for the quarter, compared to analysts' expectations of $29.18 million. On average, analysts expect that CeriBell, Inc. will post -2.05 earnings per share for the current year.
Institutional Investors Weigh In On CeriBell
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in CeriBell during the 2nd quarter worth approximately $37,657,000. KCM Capital Inc lifted its holdings in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock valued at $25,662,000 after buying an additional 400,000 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of CeriBell in the second quarter valued at approximately $17,437,000. TimesSquare Capital Management LLC purchased a new stake in shares of CeriBell in the second quarter valued at approximately $15,182,000. Finally, Bank of America Corp DE boosted its stake in shares of CeriBell by 15.3% in the first quarter. Bank of America Corp DE now owns 319,837 shares of the company's stock valued at $5,863,000 after buying an additional 42,340 shares in the last quarter.
Analyst Ratings Changes
A number of research analysts have recently issued reports on CBLL shares. BTIG Research reissued a "buy" rating on shares of CeriBell in a report on Wednesday, November 4th. Canaccord Genuity Group increased their price target on CeriBell from $26.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, November 4th. Raymond James Financial reiterated a "strong-buy" rating and issued a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. TD Cowen boosted their price objective on shares of CeriBell from $29.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, October 2nd. Finally, Barclays upgraded shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $31.25.
View Our Latest Stock Report on CeriBell
CeriBell Company Profile
(
Get Free Report)
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
